A Phase II, Open-label, Intra-patient Dose-escalation Study of Erlotinib in Patients with Advanced Non-small Cell Lung Cancer who have Failed Prior Chemotherapy
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients with Advanced Non-Small Cell Lung Cancer? Contact us by filling our your information to the right and we’ll respond to you.
Institute for Drug Development Cancer Therapy and Research Center
San Antonio, United States, 78229